We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genetic Testing Unravels Bleeding Disorders

By LabMedica International staff writers
Posted on 07 Mar 2011
A molecular approach is able to identify genes involved in life threatening bleeding disorders. More...


The rare platelet type of von Willebrand disease (PT-VWD) has similar diagnostic features to another form of the disease, 2B-VBD, and must be differentiated. A correct diagnosis can only be made by closely examining certain areas of both genes to determine where the defect lies.

An international team of scientists working in conjunction with the Queen's University, (Kingston, ON, Canada), analyzed a total of 110 samples/data from eight countries over a three year period. A molecular approach was utilized, analyzing exon 28 of the von Willebrand factor (VWF) gene, and in mutation negative cases the platelet glycoprotein Ib, alpha polypeptide (GP1BA) gene.

The investigators found that that 48 cases initially diagnosed as putative type 2B/PT-VWD carried exon 28 mutations consistent with type 2B VWD, 17 carried GP1BA mutations consistent with a PT-VWD diagnosis, three had other VWD types (2A and 2M) and five expressed three previously unpublished exon 28 mutations. In this study, the percentage of type 2B VWD diagnosis is 44%, while the percentage of misdiagnosis of PT-VWD is 15%.

The study highlights the diagnostic limitations due to unavailability or poor application of radioimmunoprecipitation assays and related tests in some centers and proposes genetic analysis as a suitable tool for the discrimination of the two disorders worldwide. Accordingly, cases that are negative for both VWF and GP1BA gene mutations require further evaluation for alternative diagnoses.

Maha Othman, MD, PhD, a professor at Queen's University, said, "Correct diagnosis is critical because it determines the treatment decision." Despite its relative rarity, VWD is actually the most common genetically inherited bleeding disorder, affecting about 1% of the general population. The study was published online in February 2011 in Thrombosis and Haemostasis.

Related Links:
Queen's University



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Candida Glabrata Test
ELIchrom Glabrata
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.